When a large animal practitioner faced treatment-resistant strongyles in sheep, with standard therapies achieving less than 10% efficacy, time-sensitive access to a foreign-approved solution became critical. Our latest case study reveals how VMD Sciences navigated complex FDA and Customs requirements to secure a highly effective treatment not yet available in the U.S., delivering >99% efficacy against multi-drug-resistant parasites.

Discover how our Managed Access Program transformed a challenging regulatory barrier into a streamlined solution, enabling the practitioner to restore flock health, optimize production outcomes, and implement sustainable parasite management, all while maintaining food safety compliance.